Prognostic Value of Circulating Biomarkers of Fibrotic Remodeling in Arrhythmogenic Cardiomyopathy.

The editorial in Biomedicines discusses the prognostic value of circulating biomarkers of fibrotic remodeling in Arrhythmogenic Cardiomyopathy (ACM). ACM is a familial heart disease with a high risk of sudden cardiac death, characterized by cardiomyocyte cell death, ventricular dysfunction, and arrhythmias. The article highlights the importance of identifying reliable biomarkers to differentiate between myocarditis and ACM, as well as the potential of circulating biomarkers to track disease progression and assess fibrotic cardiac remodeling. The study by Van der Voorn and colleagues correlates levels of circulating biomarkers with cardiac function in ACM patients, providing valuable insights into non-ischemic cardiac injury. [Extracted from the article]